Acquisition by Liu Jean I of 80000 shares of Erasca subject to Rule 16b-3
ERAS Stock | USD 2.70 0.10 3.57% |
Slightly above 56% of all Erasca's private investors are looking to take a long position. The analysis of the overall investor sentiment regarding Erasca Inc suggests that some traders are interested. Erasca's investing sentiment can be driven by a variety of factors including economic data, Erasca's earnings reports, geopolitical events, and overall market trends.
Erasca |
Filed transaction by Erasca Inc Director . Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Erasca's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Erasca's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Erasca Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Erasca can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Erasca Fundamental Analysis
We analyze Erasca's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Erasca using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Erasca based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Erasca is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Erasca Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Erasca stock to make a market-neutral strategy. Peer analysis of Erasca could also be used in its relative valuation, which is a method of valuing Erasca by comparing valuation metrics with similar companies.
Peers
Erasca Related Equities
DSGN | Design Therapeutics | 2.96 | ||||
STOK | Stoke Therapeutics | 0.81 | ||||
ARVN | Arvinas | 0.58 | ||||
BDTX | Black Diamond | 0.35 | ||||
KROS | Keros Therapeutics | 0.83 | ||||
MLYS | Mineralys Therapeutics, | 1.29 | ||||
GLUE | Monte Rosa | 1.60 | ||||
OLMA | Olema Pharmaceuticals | 1.94 | ||||
PLRX | Pliant Therapeutics | 2.11 | ||||
SANA | Sana Biotechnology | 3.17 | ||||
RLAY | Relay Therapeutics | 3.22 | ||||
EWTX | Edgewise Therapeutics | 3.28 | ||||
CGEM | Cullinan Oncology | 4.14 | ||||
ZNTL | Zentalis Pharmaceuticals | 4.93 | ||||
IPSC | Century Therapeutics | 5.88 | ||||
CCCC | C4 Therapeutics | 6.27 |
Additional Tools for Erasca Stock Analysis
When running Erasca's price analysis, check to measure Erasca's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Erasca is operating at the current time. Most of Erasca's value examination focuses on studying past and present price action to predict the probability of Erasca's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Erasca's price. Additionally, you may evaluate how the addition of Erasca to your portfolios can decrease your overall portfolio volatility.